|
US20090047255A1
(en)
*
|
2006-11-03 |
2009-02-19 |
Alphavax, Inc. |
Alphavirus and Alphavirus Replicon Particle Formulations and Methods
|
|
US20090111099A1
(en)
*
|
2007-10-27 |
2009-04-30 |
Yongsheng Ma |
Promoter Detection and Analysis
|
|
US8067241B2
(en)
*
|
2009-08-26 |
2011-11-29 |
General Electric Company |
Method and apparatus for antigen retrieval process
|
|
EP2529020B1
(en)
|
2010-01-28 |
2018-04-25 |
The Children's Hospital of Philadelphia |
A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
|
|
SG184833A1
(en)
|
2010-04-14 |
2012-11-29 |
Emd Millipore Corp |
Methods of producing high titer, high purity virus stocks and methods of use thereof
|
|
WO2012018628A1
(en)
|
2010-07-26 |
2012-02-09 |
Board Of Regents, The University Of Texas System |
Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
|
|
EP2686423A4
(en)
*
|
2011-03-14 |
2015-01-28 |
Nat Res Council Canada |
Method of viral production in cells
|
|
EP2782596A4
(en)
|
2011-11-22 |
2015-07-29 |
Philadelphia Children Hospital |
VIRUS VECTORS FOR HIGHLY EFFICIENT TRANSGENIC ADMINISTRATION
|
|
PT2790737T
(pt)
|
2011-12-12 |
2019-02-28 |
Childrens Hospital Philadelphia |
Sistema de produção de vetores lentivirais a grande escala comercial e vetores produzidos pelo mesmo
|
|
US9974850B2
(en)
|
2013-01-25 |
2018-05-22 |
Board Of Regents, The University Of Texas System |
Immunogenic compositions and uses thereof
|
|
RS57864B1
(sr)
*
|
2013-06-17 |
2018-12-31 |
De Staat Der Nederlanden Vert Door De Minister Van Vws Ministerie Van Volksgezondheid Welzijn En Spo |
Postupci za sprečavanje agregacije virusnih komponenti
|
|
CN105765066B
(zh)
|
2013-11-29 |
2018-12-14 |
宝生物工程株式会社 |
用于定量腺伴随病毒的方法
|
|
ES2744565T3
(es)
|
2014-04-25 |
2020-02-25 |
Genethon |
Tratamiento de la hiperbilirrubinemia
|
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
US10526583B2
(en)
|
2014-07-02 |
2020-01-07 |
University Of Florida Research Foundation, Incorporated |
Compositions and methods for purifying recombinant adeno-associated virus
|
|
EP3215191B1
(en)
|
2014-11-05 |
2024-08-14 |
Voyager Therapeutics, Inc. |
Aadc polynucleotides for the treatment of parkinson's disease
|
|
CN114717264A
(zh)
|
2014-11-14 |
2022-07-08 |
沃雅戈治疗公司 |
治疗肌萎缩性侧索硬化(als)的组合物和方法
|
|
KR20230145206A
(ko)
|
2014-11-14 |
2023-10-17 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
SG11201704919SA
(en)
*
|
2015-01-13 |
2017-07-28 |
Alfa Wassermann Inc |
Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav)
|
|
EP3054007A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
|
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
CN108463211B
(zh)
|
2015-11-16 |
2022-09-27 |
全国儿童医院研究所 |
用于治疗肌联蛋白类肌病和其它肌联蛋白病变的材料和方法
|
|
US11015174B2
(en)
*
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV8
|
|
ES2938833T3
(es)
*
|
2016-03-28 |
2023-04-17 |
Ultragenyx Pharmaceutical Inc |
Métodos de inactivación térmica de adenovirus
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
EP3448987A4
(en)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
US10584337B2
(en)
|
2016-05-18 |
2020-03-10 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
IL297576B2
(en)
|
2016-05-18 |
2024-02-01 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
AU2017299779B2
(en)
*
|
2016-07-21 |
2021-12-02 |
Spark Therapeutics, Inc. |
Scalable high recovery methods for producing high yield recombinant adeno-associated viral (rAAV) vector and recombinant adeno-associated viral (rAAV) vectors produced thereby
|
|
WO2018039375A1
(en)
|
2016-08-23 |
2018-03-01 |
Akouos, Inc. |
Compositions and methods for treating non-age-associated hearing impairment in a human subject
|
|
EP3831281B1
(en)
|
2016-08-30 |
2026-02-25 |
The Regents of The University of California |
Devices and systems for biomedical targeting and delivery
|
|
EP3293260A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3293259A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3293203A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
KR102617502B1
(ko)
|
2016-09-12 |
2023-12-26 |
제네똥 |
산-알파 글루코시다제 변이체 및 이의 용도
|
|
EP3512939B1
(en)
|
2016-09-16 |
2026-06-17 |
Leukocare AG |
A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
|
|
CN110300591A
(zh)
|
2016-11-04 |
2019-10-01 |
百深公司 |
腺相关病毒制剂
|
|
US10626376B2
(en)
|
2016-11-14 |
2020-04-21 |
St. Jude Children's Research Hospital |
Method for isolating and purifying adeno-associated virus particles using salt
|
|
US10294452B2
(en)
*
|
2016-11-22 |
2019-05-21 |
Dao-Yao He |
Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
|
|
WO2018141865A1
(en)
|
2017-02-01 |
2018-08-09 |
Centre National De La Recherche Scientifique |
Particles and compositions comprising the same for transfection
|
|
MA47820A
(fr)
|
2017-03-10 |
2020-01-15 |
Genethon |
Traitement de la glycogénose de type iii
|
|
MX2019013172A
(es)
|
2017-05-05 |
2020-09-07 |
Voyager Therapeutics Inc |
Composiciones y metodos para tratar la enfermedad de huntington.
|
|
EP3618839A4
(en)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
CA3070087A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
|
US11512327B2
(en)
|
2017-08-03 |
2022-11-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of AAV
|
|
MX2020003042A
(es)
|
2017-09-29 |
2020-11-18 |
Voyager Therapeutics Inc |
Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
EP4585229A3
(en)
*
|
2017-11-08 |
2026-01-14 |
Novartis AG |
Means and method for preparing viral vectors and uses of same
|
|
WO2019113202A1
(en)
*
|
2017-12-05 |
2019-06-13 |
Applied Genetic Technologies Corporation |
Formulation optimization for viral particles
|
|
AU2019216257B2
(en)
|
2018-01-31 |
2025-11-20 |
Research Institute At Nationwide Children's Hospital |
Gene therapy for limb-girdle muscular dystrophy type 2C
|
|
CA3086942A1
(en)
|
2018-02-07 |
2019-08-15 |
Genethon |
Hybrid regulatory elements
|
|
IL325122A
(en)
|
2018-02-22 |
2026-02-01 |
Akouos Inc |
Compositions and methods for treating non-age-related hearing impairment in humans
|
|
EP3762500A1
(en)
|
2018-03-06 |
2021-01-13 |
Voyager Therapeutics, Inc. |
Insect cell manufactured partial self-complementary aav genomes
|
|
CA3097192A1
(en)
|
2018-04-27 |
2019-10-31 |
Voyager Therapeutics, Inc. |
Methods for measuring the potency of aadc viral vectors
|
|
CN112424359A
(zh)
|
2018-05-15 |
2021-02-26 |
沃雅戈治疗公司 |
用于治疗帕金森氏病的组合物和方法
|
|
US20210207167A1
(en)
|
2018-05-16 |
2021-07-08 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
|
WO2019222444A2
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Directed evolution
|
|
JP7478675B2
(ja)
|
2018-06-08 |
2024-05-07 |
ノバルティス アーゲー |
薬物製品の効力を測定するための細胞ベースアッセイ
|
|
IL279789B2
(en)
|
2018-06-29 |
2026-04-01 |
Res Inst Nationwide Childrens Hospital |
Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2A
|
|
EP3814492A4
(en)
|
2018-06-29 |
2022-02-23 |
Wuhan Neurophth Biotechnology Limited Company |
Compositions and methods for treating leber's hereditary optic neuropathy
|
|
US20210254103A1
(en)
|
2018-07-02 |
2021-08-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
|
MX2020013953A
(es)
|
2018-07-11 |
2021-03-09 |
Takeda Pharmaceuticals Co |
Composiciones de virus adenoasociado (aav).
|
|
WO2020023612A1
(en)
|
2018-07-24 |
2020-01-30 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
CA3107572A1
(en)
|
2018-08-08 |
2020-02-13 |
Genethon |
Mini-gde for the treatment of glycogen storage disease iii
|
|
WO2020033842A1
(en)
*
|
2018-08-10 |
2020-02-13 |
Regenxbio Inc. |
Scalable method for recombinant aav production
|
|
KR20210068014A
(ko)
|
2018-08-20 |
2021-06-08 |
우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 |
레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
|
|
US12281321B2
(en)
|
2018-09-28 |
2025-04-22 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
WO2020072849A1
(en)
|
2018-10-04 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
CA3125770A1
(en)
|
2019-01-18 |
2020-07-23 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
KR20210133242A
(ko)
|
2019-02-26 |
2021-11-05 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
B-사르코글리칸의 아데노 관련 바이러스 벡터 전달 및 근이영양증의 치료
|
|
KR20210148273A
(ko)
|
2019-04-08 |
2021-12-07 |
제네똥 |
근육 발현을 위한 하이브리드 프로모터
|
|
JP7630443B2
(ja)
*
|
2019-04-19 |
2025-02-17 |
レジェンクスバイオ インコーポレーテッド |
アデノ随伴ウイルスベクター製剤及び方法
|
|
EP3956354A1
(en)
|
2019-04-19 |
2022-02-23 |
Genethon |
Gene therapy of fibroblast growth factor 23 related hypophosphatemic diseases
|
|
US20220243225A1
(en)
|
2019-04-29 |
2022-08-04 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
|
CN114174514A
(zh)
|
2019-07-25 |
2022-03-11 |
诺华股份有限公司 |
可调节的表达系统
|
|
EP4010465A1
(en)
|
2019-08-09 |
2022-06-15 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
EP4013436A1
(en)
|
2019-08-14 |
2022-06-22 |
Leukocare Ag |
Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
|
|
US11401530B2
(en)
|
2019-08-19 |
2022-08-02 |
The Catholic University Of America |
Bacteriophage-based artificial viruses for human genome remodeling
|
|
US11155835B2
(en)
*
|
2019-08-19 |
2021-10-26 |
The Catholic University Of America |
Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
|
|
CA3150964A1
(en)
|
2019-08-21 |
2021-02-25 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
|
|
EP4022070A1
(en)
|
2019-08-26 |
2022-07-06 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2021071835A1
(en)
|
2019-10-07 |
2021-04-15 |
Regenxbio Inc. |
Adeno-associated virus vector pharmaceutical composition and methods
|
|
US12662512B2
(en)
|
2019-10-22 |
2026-06-23 |
Genethon |
Chimeric polypeptides and uses thereof
|
|
WO2021078834A1
(en)
|
2019-10-22 |
2021-04-29 |
Genethon |
Chimeric acid-alpha glucosidase polypeptides and uses thereof
|
|
CN113025633B
(zh)
|
2019-12-09 |
2024-08-27 |
武汉纽福斯生物科技有限公司 |
编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
|
|
KR102167829B1
(ko)
*
|
2020-02-10 |
2020-10-20 |
주식회사 이노테라피 |
아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법
|
|
AU2021218703A1
(en)
|
2020-02-14 |
2022-07-28 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating CDKL5 deficiency disorder
|
|
CA3168055A1
(en)
|
2020-02-21 |
2021-08-26 |
Emmanuel John Simons |
Compositions and methods for treating non-age-associated hearing impairment in a human subject
|
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
|
EP3913060A1
(en)
|
2020-05-22 |
2021-11-24 |
Genethon |
Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
|
|
CN116096867A
(zh)
*
|
2020-06-02 |
2023-05-09 |
詹森生物科技公司 |
用于病毒纯化的材料和方法
|
|
EP4192514A1
(en)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
WO2022032104A1
(en)
*
|
2020-08-07 |
2022-02-10 |
Janssen Biotech, Inc. |
Formulations for highly purified viral particles
|
|
JP2023539219A
(ja)
|
2020-08-24 |
2023-09-13 |
ジェネトン |
糖原病ｉｉｉの治療のためのｃ末端切断ｇｄｅ
|
|
KR20230078805A
(ko)
|
2020-11-02 |
2023-06-02 |
바이오마린 파머수티컬 인크. |
아데노-연관 바이러스의 농축 공정
|
|
US20240067942A1
(en)
|
2020-12-09 |
2024-02-29 |
Genethon |
Lysosomal acid lipase variants and uses thereof
|
|
WO2022187473A2
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2022187548A1
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2022208342A1
(en)
*
|
2021-04-01 |
2022-10-06 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
|
WO2022236008A1
(en)
*
|
2021-05-07 |
2022-11-10 |
Board Of Regents, The University Of Texas System |
Methods and compositions for transport, storage, and delivery of adeno-associated viral vector and other molecules
|
|
WO2023012313A1
(en)
|
2021-08-04 |
2023-02-09 |
Genethon |
Hybrid promoters for gene expression in muscles and in the cns
|
|
JP2024534410A
(ja)
|
2021-09-16 |
2024-09-20 |
ノバルティス アーゲー |
新規転写因子
|
|
US12285497B2
(en)
|
2021-10-15 |
2025-04-29 |
Research Institute At Nationwide Children's Hospital |
Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
|
|
JP2024539123A
(ja)
|
2021-10-25 |
2024-10-28 |
ノバルティス アーゲー |
アデノ随伴ウイルス（ａａｖ）送達を改善する方法
|
|
WO2023175584A1
(en)
|
2022-03-17 |
2023-09-21 |
Innoskel |
Polynucleotides encoding the alpha-1 chain of human type ii collagen and methods of their use
|
|
WO2023175585A1
(en)
|
2022-03-17 |
2023-09-21 |
Innoskel |
Hybrid promoters and their use in osteolysis syndrome
|
|
CA3255627A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
NEW VP2 FUSION POLYPEPTIDES OF RECOMBINANT AAV
|
|
WO2023237731A1
(en)
|
2022-06-09 |
2023-12-14 |
Genethon |
N-terminal truncated gde for the treatment of glycogen storage disease iii
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
TW202426017A
(zh)
*
|
2022-11-24 |
2024-07-01 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
非包膜病毒的藥物組合物
|
|
KR20260025090A
(ko)
*
|
2023-06-09 |
2026-02-23 |
4디 몰레큘러 테라퓨틱스 아이엔씨. |
아데노-연관 바이러스 제형
|
|
WO2025003477A1
(en)
|
2023-06-29 |
2025-01-02 |
Genethon |
N-terminal truncated glycogen debranching enzymes for the treatment of glycogen storage disease iii
|
|
EP4606892A1
(en)
|
2024-02-23 |
2025-08-27 |
Merck Patent GmbH |
Methods for the production of viral particles
|
|
WO2026150302A1
(en)
|
2025-01-09 |
2026-07-16 |
Novartis Ag |
Novel aav rep/cap encoding constructs
|